Physician profile
James Christopher Goetz
NPI 1700827714
$1,178.52
in general payments reported to CMS, 2019-2025
10 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $123 · 2021: $125 · 2022: $180 · 2023: $148 · 2024: $12.70 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.14 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.08 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $125.00 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $114.54 | 2023 | Jynarque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.94 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $89.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $58.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $46.26 | 2019 | |
| Pfizer INC. | $31.04 | 2019 | |
| Advanced Respiratory, INC | $15.21 | 2019 | |
| Gilead Sciences, INC. | $10.53 | 2023 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Goetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.